Traduction de «aged 40-49 years at average » (Français → Néerlandais) :

13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

Âge Régime général Régime indépendant Total non-BIM BIM Total Total général 0 à 9 ans 104,91 106,02 98,04 97,63 106,03 131,60 125,41 128,02 107,06 10 à 19 ans 102,24 110,87 102,54 103,94 107,49 110,95 117,19 113,95 107,86 20 à 29 ans 105,94 106,52 101,38 95,96 106,20 110,49 113,12 111,62 106,40 30 à 39 ans 105,43 104,78 100,46 100,43 106,03 111,34 116,19 113,70 106,59 40 à 49 ans 105,78 106,05 103,78 98,43 106,66 111,56 113,97 112,89 107,17 50 à 59 ans 105,00 106,49 106,88 106,42 106,01 109,35 108,74 108,97 106,27 60 à 69 ans 104,72 105,70 106,95 107,86 105,68 105,41 104,52 104,99 105,63 70 à 79 ans 104,09 105,79 107,04 108,20 105,53 107,31 104,80 106,05 105,57 80 à 89 ans 105,32 105,16 105,97 106,59 105,40 106,94 108,41 107,44 105,57 90 ans et + 103,41 103,64 104,37 102,75 103,30 107,86 108,14 107,90 103,77 Total 106,24 107,60 102,98 102,34 106,57 107,78 109,00 108,35 106,68
Leeftijd Algemene regeling Regeling der zelfstandigen Algemeen Zonder voorkeurregeling Met voorkeurregeling Totaal Totaal totaal 0 tot 9 jaar 104,91 106,02 98,04 97,63 106,03 131,60 125,41 128,02 107,06 10 tot 19 jaar 102,24 110,87 102,54 103,94 107,49 110,95 117,19 113,95 107,86 20 tot 29 jaar 105,94 106,52 101,38 95,96 106,20 110,49 113,12 111,62 106,40 30 tot 39 jaar 105,43 104,78 100,46 100,43 106,03 111,34 116,19 113,70 106,59 40 tot 49 jaar 105,78 106,05 103,78 98,43 106,66 111,56 113,97 112,89 107,17 50 tot 59 jaar 105,00 106,49 106,88 106,42 106,01 109,35 108,74 108,97 106,27 60 tot 69 jaar 104,72 105,70 106,95 107,86 105,68 105,41 104,52 104,99 105,63 70 tot 79 jaar 104,09 105,79 107,04 108,20 105,53 107,31 104,80 106,05 105,57 80 tot 89 jaar 105,32 105,16 105,97 106,59 105,40 106,94 108,41 107,44 105,57 90 jaar en + 103,41 103,64 104,37 102,75 103,30 107,86 108,14 107,90 103,77 Totaal 106,24 107,60 102,98 102,34 106,57 107,78 109,00 108,35 106,68

Coût moyen par bénéficiaire en 2006 (en EUR) FEmmes - HOmmes âge Régime général Régime indépendant Total non BIM BIM Total Total général jusqu’à 9 ans 564,88 697,07 1 719,06 2 214,71 716,95 323,42 423,14 374,36 696,90 10 à 19 ans 488,22 463,40 1 334,42 1 421,58 562,22 286,40 287,31 286,87 539,38 20 à 29 ans 884,76 495,30 2 150,39 2 544,30 805,12 499,88 248,29 361,84 775,74 30 à 39 ans 1 087,71 616,97 3 526,15 4 073,28 1 011,08 653,00 278,07 421,40 947,29 40 à 49 ans 1 078,67 863,35 3 934,22 5 181,28 1 205,72 570,05 455,75 499,42 1 113,75 50 à 59 ans 1 470,82 1 411,79 3 487,06 4 493,39 1 763,86 942,48 923,49 931,20 1 663,41 60 à 69 ans 2 047,23 2 271,11 3 779,11 4 494,71 2 531,29 1 684,46 2 016,52 1 860,09 2 470,17 70 à 79 ans 3 278,06 3 661,28 5 175,54 5 716,30 4 011,71 2 903,37 3 313,07 3 091,68 3 934,49 80 à 89 ans 5 803,77 5 440,65 8 078,40 7 634,02 6 607,90 5 603,87 4 869,75 5 315,14 6 497,72 90 ans et plus 10 191,26 8 359,94 12 410,25 11 048,24 11 122,01 9 826,26 8 119,78 9 374,53 10 927,53 Total 1 422,64 1 212,95 4 770,22 4 407,03 1 737,93 1 292,88 935,35 1 093,17 1 676,64
Gemiddelde kostprijs per rechthebbende in 2006 (in EUR) Vrouwen - mannen Leeftijd Algemene regeling Regeling der zelfstandigen Algemeen Zonder voorkeurregeling Met voorkeurregeling Totaal Totaal totaal 0 tot 9 jaar 564,88 697,07 1 719,06 2 214,71 716,95 323,42 423,14 374,36 696,90 10 tot 19 jaar 488,22 463,40 1 334,42 1 421,58 562,22 286,40 287,31 286,87 539,38 20 tot 29 jaar 884,76 495,30 2 150,39 2 544,30 805,12 499,88 248,29 361,84 775,74 30 tot 39 jaar 1 087,71 616,97 3 526,15 4 073,28 1 011,08 653,00 278,07 421,40 947,29 40 tot 49 jaar 1 078,67 863,35 3 934,22 5 181,28 1 205,72 570,05 455,75 499,42 1 113,75 50 tot 59 jaar 1 470,82 1 411,79 3 487,06 4 493,39 1 763,86 942,48 923,49 931,20 1 663,41 60 tot 69 jaar 2 047,23 2 271,11 3 779,11 4 494,71 2 531,29 1 684,46 2 016,52 1 860,09 2 470,17 70 tot 79 jaar 3 278,06 3 661,28 5 175,54 5 716,30 4 011,71 2 903,37 3 313,07 3 091,68 3 934,49 80 tot 89 jaar 5 803,77 5 440,65 8 078,40 7 634,02 6 607,90 5 603,87 4 869,75 5 315,14 6 497,72 90 jaar en meer 10 191,26 8 359,94 12 410,25 11 048,24 11 122,01 9 826,26 8 119,78 9 374,53 10 927,53 Totaal 1 422,64 1 212,95 4 770,22 4 407,03 1 737,93 1 292,88 935,35 1 093,17 1 676,64

Breast cancer (age group 40 - 49) : observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)
Breast cancer (age group 40 - 49): observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)

Table 20 : Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)
Table 20: Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)

Coût moyen par bénéficiaire en 2007 (en EUR) FEmmes - HOmmes âge Régime général Régime indépendant Total non BIM BIM Total Total général jusqu’à 9 ans 591,24 740,47 1 781,91 2 371,49 764,47 366,05 481,28 424,93 743,30 10 à 19 ans 515,49 484,72 1 494,56 1 629,31 605,69 303,26 329,48 316,69 581,33 20 à 29 ans 930,02 522,57 2 271,84 2 588,46 853,21 565,57 271,21 402,66 822,42 30 à 39 ans 1 144,13 650,62 3 619,62 4 103,14 1069,88 694,53 299,82 448,68 1 001,71 40 à 49 ans 1 143,18 909,87 4 041,90 5 278,91 1276,99 607,83 476,40 526,03 1 177,81 50 à 59 ans 1 543,38 1 499,82 3 714,67 4 661,00 1862,33 986,12 953,66 966,60 1 754,10 60 à 69 ans 2 132,52 2 378,08 4 005,15 4 685,53 2642,22 1 801,45 2 094,73 1958,26 2 580,71 70 à 79 ans 3 433,07 3 806,97 5 497,16 5 995,15 4196,14 3 095,79 3 565,26 3310,92 4 121,47 80 à 89 ans 6 061,51 5 727,25 8 567,62 8 031,09 6944,21 5 996,06 5 256,82 5703,95 6 835,64 90 ans et + 10 649,99 9 005,19 12 968,02 11 649,20 11 641,71 10 485,31 8 447,11 9934,51 11 452,51 Total 1504,16 1286,69 4987,00 4575,09 1838,09 1382,70 992,28 1163,33 1 773,06
Gemiddelde kostprijs per rechthebbende in 2007 (in EUR) VROUWEN - MANNEN Leeftijd Algemene regeling Regeling der zelfstandigen Algemeen Zonder voorkeurregeling Met voorkeurregeling Totaal Totaal totaal 0 tot 9 jaar 591,24 740,47 1 781,91 2 371,49 764,47 366,05 481,28 424,93 743,30 10 tot 19 jaar 515,49 484,72 1 494,56 1 629,31 605,69 303,26 329,48 316,69 581,33 20 tot 29 jaar 930,02 522,57 2 271,84 2 588,46 853,21 565,57 271,21 402,66 822,42 30 tot 39 jaar 1 144,13 650,62 3 619,62 4 103,14 1069,88 694,53 299,82 448,68 1 001,71 40 tot 49 jaar 1 143,18 909,87 4 041,90 5 278,91 1276,99 607,83 476,40 526,03 1 177,81 50 tot 59 jaar 1 543,38 1 499,82 3 714,67 4 661,00 1862,33 986,12 953,66 966,60 1 754,10 60 tot 69 jaar 2 132,52 2 378,08 4 005,15 4 685,53 2642,22 1 801,45 2 094,73 1958,26 2 580,71 70 tot 79 jaar 3 433,07 3 806,97 5 497,16 5 995,15 4196,14 3 095,79 3 565,26 3310,92 4 121,47 80 tot 89 jaar 6 061,51 5 727,25 8 567,62 8 031,09 6944,21 5 996,06 5 256,82 5703,95 6 835,64 90 jaar en + 10 649,99 9 005,19 12 968,02 11 649,20 11 641,71 10 485,31 8 447,11 9934,51 11 452,51 Totaal 1504,16 1286,69 4987,00 4575,09 1838,09 1382,70 992,28 1163,33 1 773,06

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Table 4: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words
Table 2: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words

Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. preventive services task force.